Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.

Nantes University Hospital (NUH)

Status: Terminated

Conditions: Multiple Myeloma

Treatments: Drug: FDG = fluorodeoxyglucose

Study type: Interventional

Funder types: Other

Identifiers

NCT00200668

BRD/04/6-H

Details and patient eligibility

About

Comparison between FDG-PET and MRI for the assessment of response to intensive chemotherapy in multiple myeloma patients.

Full description

First whole body FDG-PET scan and MRI before the start of the treatment. Second whole body FDG-PET scan and MRI after the end of the treatment. On a basis of patient, comparison between PET and MRI will be done tumoral site by site. Sensitivity, Specificity will be estimated for both techniques. In case of discrepancy, another imaging method or biopsy (if easy to perform) will be serve as standard of reference. Kappa coefficients and Mc Nemar test will be performed to compare the two methods. FDG = fluorodeoxyglucose FLUCIS® (Schering-CisBio® international)

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients from 18 to 65 years old.
• De novo histologically proven multiple myeloma.

Exclusion criteria

• No history of another cancer or of HIV
• No history of renal failure

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)